Charles River Laboratories International, Inc. (CRL)
USD 99.06
(-0.9%)
USD 99.06
(-0.9%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 1.03 Billion USD | 4.66% |
| 2022 | 1.03 Billion USD | 20.24% |
| 2021 | 854.29 Million USD | 6.73% |
| 2020 | 759.14 Million USD | 36.48% |
| 2019 | 581.73 Million USD | 37.24% |
| 2018 | 507.23 Million USD | 11.46% |
| 2017 | 457.89 Million USD | 25.92% |
| 2016 | 377.28 Million USD | 26.73% |
| 2015 | 305.38 Million USD | 13.28% |
| 2014 | 285.99 Million USD | 20.34% |
| 2013 | 255.54 Million USD | -7.96% |
| 2012 | 244.36 Million USD | -6.26% |
| 2011 | 260.47 Million USD | 60.38% |
| 2010 | -205.15 Million USD | -36.74% |
| 2009 | 263.2 Million USD | -80.41% |
| 2008 | -355.81 Million USD | 210.65% |
| 2007 | 321.8 Million USD | 16.61% |
| 2006 | 273.3 Million USD | -4.73% |
| 2005 | 274.81 Million USD | 37.57% |
| 2004 | 210.64 Million USD | 23.02% |
| 2003 | 138.55 Million USD | 15.07% |
| 2002 | 147.99 Million USD | 24.0% |
| 2001 | 90.28 Million USD | 42.89% |
| 2000 | 83.93 Million USD | 46.33% |
| 1999 | 58.6 Million USD | 22.32% |
| 1998 | 46.22 Million USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | 255.68 Million USD | 8.72% |
| 2024 Q1 | 228.33 Million USD | -32.03% |
| 2023 Q4 | 322.76 Million USD | 43.14% |
| 2023 Q3 | 225.48 Million USD | -6.58% |
| 2023 Q2 | 241.37 Million USD | -0.46% |
| 2023 FY | - USD | 4.66% |
| 2023 Q1 | 242.49 Million USD | -23.05% |
| 2022 Q1 | 195.57 Million USD | -4.77% |
| 2022 Q3 | 209.08 Million USD | -21.16% |
| 2022 Q4 | 315.13 Million USD | 50.72% |
| 2022 FY | - USD | 20.24% |
| 2022 Q2 | 265.19 Million USD | 35.6% |
| 2021 Q3 | 208.41 Million USD | 17.98% |
| 2021 Q1 | 157.52 Million USD | -32.56% |
| 2021 Q4 | 205.38 Million USD | -1.45% |
| 2021 FY | - USD | 6.73% |
| 2021 Q2 | 176.65 Million USD | 12.14% |
| 2020 Q2 | 160.51 Million USD | 25.61% |
| 2020 FY | - USD | 36.48% |
| 2020 Q4 | 233.58 Million USD | 9.29% |
| 2020 Q3 | 213.72 Million USD | 33.15% |
| 2020 Q1 | 127.78 Million USD | -16.94% |
| 2019 Q4 | 153.85 Million USD | 17.72% |
| 2019 Q1 | 121.63 Million USD | 11.79% |
| 2019 Q2 | 128.97 Million USD | 6.03% |
| 2019 Q3 | 130.69 Million USD | 1.33% |
| 2019 FY | - USD | 37.24% |
| 2018 FY | - USD | 11.46% |
| 2018 Q3 | 134.09 Million USD | 1.34% |
| 2018 Q4 | 108.8 Million USD | -18.86% |
| 2018 Q2 | 132.32 Million USD | 23.16% |
| 2018 Q1 | 107.44 Million USD | 23.16% |
| 2017 Q3 | 114.07 Million USD | -1.76% |
| 2017 Q2 | 116.11 Million USD | -1.13% |
| 2017 Q1 | 117.44 Million USD | 40.57% |
| 2017 Q4 | 87.23 Million USD | -23.53% |
| 2017 FY | - USD | 25.92% |
| 2016 Q4 | 83.54 Million USD | -11.54% |
| 2016 Q1 | 80.41 Million USD | 36.04% |
| 2016 Q3 | 94.44 Million USD | -1.26% |
| 2016 Q2 | 95.65 Million USD | 18.95% |
| 2016 FY | - USD | 26.73% |
| 2015 FY | - USD | 13.28% |
| 2015 Q1 | 48.26 Million USD | 0.73% |
| 2015 Q2 | 87.85 Million USD | 82.03% |
| 2015 Q3 | 80.82 Million USD | -8.0% |
| 2015 Q4 | 59.11 Million USD | -26.86% |
| 2014 Q2 | 78.21 Million USD | 18.8% |
| 2014 Q4 | 47.91 Million USD | -10.93% |
| 2014 FY | - USD | 20.34% |
| 2014 Q1 | 65.83 Million USD | 123.02% |
| 2014 Q3 | 53.79 Million USD | -31.23% |
| 2013 FY | - USD | -7.96% |
| 2013 Q4 | 29.52 Million USD | -34.43% |
| 2013 Q3 | 45.02 Million USD | -30.52% |
| 2013 Q2 | 64.8 Million USD | 37.84% |
| 2013 Q1 | 47.01 Million USD | 18.42% |
| 2012 Q2 | 69.49 Million USD | 44.07% |
| 2012 FY | - USD | -6.26% |
| 2012 Q3 | 42.21 Million USD | -39.25% |
| 2012 Q1 | 48.23 Million USD | -31.5% |
| 2012 Q4 | 39.7 Million USD | -5.95% |
| 2011 Q1 | 47.63 Million USD | -16.41% |
| 2011 Q2 | 59.11 Million USD | 24.1% |
| 2011 Q3 | 42.37 Million USD | -28.32% |
| 2011 Q4 | 70.41 Million USD | 66.18% |
| 2011 FY | - USD | 60.38% |
| 2010 Q2 | 34.97 Million USD | -5.7% |
| 2010 FY | - USD | -36.74% |
| 2010 Q1 | 37.08 Million USD | -34.04% |
| 2010 Q3 | 29.5 Million USD | -15.64% |
| 2010 Q4 | 56.98 Million USD | 93.13% |
| 2009 FY | - USD | -80.41% |
| 2009 Q1 | 62.49 Million USD | -20.18% |
| 2009 Q2 | 56.31 Million USD | -9.88% |
| 2009 Q3 | 51.15 Million USD | -9.17% |
| 2009 Q4 | 56.22 Million USD | 9.91% |
| 2008 Q4 | 78.28 Million USD | -15.41% |
| 2008 FY | - USD | 210.65% |
| 2008 Q3 | 92.54 Million USD | -0.07% |
| 2008 Q2 | 92.61 Million USD | 6.85% |
| 2008 Q1 | 86.67 Million USD | 14.57% |
| 2007 Q2 | 79.66 Million USD | 5.98% |
| 2007 FY | - USD | 16.61% |
| 2007 Q1 | 75.16 Million USD | 13.78% |
| 2007 Q3 | 87.07 Million USD | 9.31% |
| 2007 Q4 | 75.64 Million USD | -13.13% |
| 2006 Q4 | 66.06 Million USD | -9.94% |
| 2006 Q1 | 66.97 Million USD | 7.3% |
| 2006 Q2 | 66.56 Million USD | -0.61% |
| 2006 FY | - USD | -4.73% |
| 2006 Q3 | 73.35 Million USD | 10.2% |
| 2005 Q1 | 71.61 Million USD | 28.05% |
| 2005 Q2 | 76.19 Million USD | 6.4% |
| 2005 Q3 | 75.6 Million USD | -0.77% |
| 2005 Q4 | 62.41 Million USD | -17.44% |
| 2005 FY | - USD | 37.57% |
| 2004 FY | - USD | 23.02% |
| 2004 Q1 | 47.49 Million USD | 9.96% |
| 2004 Q2 | 52.41 Million USD | 10.35% |
| 2004 Q3 | 51.94 Million USD | -0.91% |
| 2004 Q4 | 55.92 Million USD | 7.67% |
| 2003 FY | - USD | 15.07% |
| 2003 Q3 | 34.25 Million USD | -0.35% |
| 2003 Q4 | 44.28 Million USD | 3.14% |
| 2003 Q1 | 33.84 Million USD | 8.98% |
| 2003 Q2 | 35 Million USD | 2.38% |
| 2002 Q4 | 37.85 Million USD | -4.42% |
| 2002 Q3 | 32.51 Million USD | 11.31% |
| 2002 Q2 | 30.38 Million USD | 3.21% |
| 2002 Q1 | 28.41 Million USD | 11.8% |
| 2002 FY | - USD | 24.0% |
| 2001 Q1 | 25.26 Million USD | 35.85% |
| 2001 FY | - USD | 42.89% |
| 2001 Q4 | 30.66 Million USD | -2.31% |
| 2001 Q3 | 24.01 Million USD | -0.48% |
| 2001 Q2 | 24.49 Million USD | 27.71% |
| 2000 FY | - USD | 46.33% |
| 2000 Q4 | 18.58 Million USD | -20.22% |
| 2000 Q3 | 22.52 Million USD | 16.23% |
| 2000 Q1 | 22.84 Million USD | 0.0% |
| 2000 Q2 | 19.98 Million USD | -11.75% |
| 1999 FY | - USD | 22.32% |
| 1998 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Agilent Technologies, Inc. | 1.67 Billion USD | 38.455% |
| Quest Diagnostics Incorporated | 1.73 Billion USD | 40.409% |
| Danaher Corporation | 7.54 Billion USD | 86.324% |
| Enzo Biochem, Inc. | -8.34 Million USD | 12463.656% |
| IQVIA Holdings Inc. | 3.25 Billion USD | 68.301% |
| Laboratory Corporation of America Holdings | 1.34 Billion USD | 23.513% |
| Mettler-Toledo International Inc. | 1.18 Billion USD | 12.766% |
| Qiagen N.V. | 650.58 Million USD | -58.645% |
| Revvity, Inc. | 813.25 Million USD | -26.912% |
| Thermo Fisher Scientific Inc. | 10.8 Billion USD | 90.443% |
| Waters Corporation | 1.02 Billion USD | -0.965% |